SynAging announces extension of its collaboration with Europe's largest biopharmaceutical company Download PDF
First Commercial in vitro Test System for Human Neuroprotection in Proteopathic Diseases such as Alzheimer’s and Parkinson’s Download PDF
SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology Download PDF, 150 KB
Human neuronal cultures challenged by human tau oligomers (hTO)
iPS cell derived human neuronal cultures (see here) are challenged with SynAging's hTO preparation for seven days to mimic Alzheimer's dementia in vitro. Client’s therapeutic candidates are applied before, concomitantly, or after this challenge. Our readout for human neuronal survival in this mixed culture (40% neurons, 60% astroglia) is an ELISA for neuron specific emolase (NSE) as a arker for neuronal survival.
Product Sheet “In vitro Screen using Human Tau Oligomers”, will become available soon